This website is intended for healthcare professionals only.
Prof. Paresh Vyas
DPhil, FRCPath, FRCP, FMedSci
Professor of Haematology
Weatherall Institute of Molecular Medicine, Oxford
Dr. Peter Valk PhD
Department of Hematology
Erasmus Medical Center The Netherlands
Key points covered
This webinar conversation the following points:
The importance of molecular testing for AML risk stratification and treatment decisions
The clinical relevance of IDH1 mutation (mIDH1)
How to test for mIDH1 (PCR vs NGS), and when we should be testing
Current treatment options for patients with mIDH1 AML ineligible for intensive chemotherapy
Patient profile demonstrating the benefit of early molecular testing and targeted treatment with an mIDH1 inhibitor
Webinar Replay
Featured Speakers
Prof. Paresh Vyas DPhil, FRCPath, FRCP, FMedSci
Professor of Haematology
Weatherall Institute of Molecular Medicine, Oxford
Professor Paresh Vyas is a clinical academic and Deputy Director of the MRC Molecular Haematology Unit (MHU), Weatherall Institute of Molecular Medicine (WIMM) at the University of Oxford. He is clinical lead for AML (Acute Myeloid Leukaemia) and MDS (Myelodysplasia) for Oxford and leads Phase I-III clinical trials in the UK and internationally in AML and MDS.
His research focuses on the molecular and cellular biology of normal and leukaemic haemopoiesis, AML therapy, clonal haemopoiesis and allo-immune responses to leukaemia.
Dr. Peter Valk, PhD
Department of Hematology
Erasmus Medical Center The Netherlands
Dr. Peter J.M. Valk received his PhD degree in 1999 at the Department of Hematology at Erasmus University Rotterdam, on the identification of novel leukemia oncogenes using retroviral mutagenesis (with Prof. Dr. B. Löwenberg). He worked as a research fellow awarded by the Dutch Cancer Society in the Department of Hemato-oncology at the Children’s Hospital in Boston (with Prof. Stuart Orkin). In 2000, Dr. Valk returned to the Department of Hematology at the Erasmus University Medical Center as Associate Professor and Head of the Hemato-oncology Laboratory (cytology and molecular diagnostics – reference laboratory in HOVON-AMLSG-NCRI clinical trials).